Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist

By Shibasaki M.   Fujimori A.   Takanashi M.   Kusayama T.   Tokioka T.   Satoh Y.   Okazaki T.   Uchida W.   Inagaki O.   Yanagisawa I.  

European Journal of Pharmacology, Vol. 335, Iss. 2, 1997-09 ,pp. : 167-173

Elsevier

Access to resources Recommend Favorite

The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials

By Mistry Nisha B   Westheim Arne S   Kjeldsen Sverre E  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 5, 2006-04 ,pp. : 575-581

Informa Healthcare

Access to resources Recommend Favorite

Comparative effects of tamoxifen and angiotensin II type-1 receptor antagonist therapy on the hemodynamic profile of the ovariectomized female rat

By Pham-Dang My-Lan   Clement Robert   Mercier Isabelle   Calderone Angelino  

Canadian Journal of Physiology and Pharmacology, Vol. 81, Iss. 9, 2003-09 ,pp. : 915-919

NRC Research Press

Access to resources Recommend Favorite

Renal pharmacology of GR138950, a novel non-peptide angiotensin AT 1 receptor antagonist

By Clark K.L.   Robertson M.J.   Drew G.M.  

European Journal of Pharmacology, Vol. 280, Iss. 2, 1995-07 ,pp. : 195-203

Elsevier

Access to resources Recommend Favorite

Effects of a novel angiotensin AT 1 receptor antagonist, HR720, on rats with myocardial infarction

By Xia Q.-G.   Chung O.   Spitznagel H.   Sandmann S.   Illner S.   Rossius B.   Jahnichen G.   Reinecke A.   Gohlke P.   Unger T.  

European Journal of Pharmacology, Vol. 385, Iss. 2, 1999-12 ,pp. : 171-179

Elsevier

Access to resources Recommend Favorite